SCHEMBL22777883

SCHEMBL22777883

CC(C)(C)OC(=O)NCC#Cc1cnc(N2CCC(c3c[nH]c4nnc(-c5ccccc5O)cc34)CC2)nc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMARCA2 P51531 3/20 0.38
▸ SMARCA4 P51532 3/20 0.38
▸ PBRM1 Q86U86 3/20 0.38
▸ DDB1 Q16531 2/20 0.38
▸ CRBN Q96SW2 2/20 0.38
▸ JAK2 O60674 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ CKS1B P61024 1/20 0.34
▸ SKP1 P63208 1/20 0.34
▸ SKP2 Q13309 1/20 0.34
▸ BTK Q06187 1/20 0.34
▸ AXL P30530 7/20 0.34
▸ PTPN11 Q06124 1/20 0.33
▸ ACACB O00763 1/20 0.33
▸ ACACA Q13085 1/20 0.33
▸ FEN1 P39748 1/20 0.33
▸ CAMKK2 Q96RR4 1/20 0.32
▸ HSD11B1 P28845 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30382571 1.00 SMARCA2 (0.38) SMARCA2SMARCA4PBRM1DDB1CRBN
SCHEMBL22777905 0.90 PBRM1 (0.36) SMARCA2SMARCA4PBRM1BTKAXL
SCHEMBL22777873 0.86 JAK2 (0.37) SMARCA2SMARCA4PBRM1DDB1CRBN
SCHEMBL30381742 0.86 JAK2 (0.37) SMARCA2SMARCA4PBRM1DDB1CRBN
SCHEMBL22777857 0.85 PBRM1 (0.40) SMARCA2SMARCA4PBRM1BTKCAMKK2
SCHEMBL22777868 0.83 SMARCA2 (0.48) SMARCA2SMARCA4PBRM1DDB1CRBN
SCHEMBL22777626 0.78 SMARCA2 (0.54) SMARCA2SMARCA4PBRM1JAK2JAK1
SCHEMBL22777839 0.78 PBRM1 (0.41) SMARCA2SMARCA4PBRM1BTKCAMKK2
SCHEMBL22777902 0.78 PBRM1 (0.38) SMARCA2SMARCA4PBRM1BTKAXL
SCHEMBL25468671 0.77 PTPN11 (0.41) BTKPTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12521438-B2 SMARCA degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-01-13 — — US disclosed
US-20230149549-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-20230149549-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-18 — — US disclosed
US-20230149549-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-18 — — US disclosed
WO-2020251972-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-17 — — WO disclosed
WO-2020251972-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149549-A1 SMARCA DEGRADERS AND USES THEREOF SMARCA1, SMARCB1, SMARCE1 SMARCA2 6/4885SMARCA4 7/4885PBRM1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback